Federal Hemp THC Ban: Nov 12 vs Dec 11, 2026
Most federal hemp THC rules now take effect December 11, 2026. Cannabinoids the plant cannot make, such as THC-O, still change on November 12.
Most of the federal hemp THC rewrite now takes effect on December 11, 2026. November 12, 2026 stays in force only for products that contain a cannabinoid the cannabis plant cannot make on its own.
That split is Section 2019 of Public Law 119-103 (the Delay Amendment), the continuing-appropriations law signed September 2, 2026. It does not repeal Section 781 of Public Law 119-37. It does not push back November 12 for synthetic or non-natural cannabinoids. It says that, until December 11, the rest of the Section 781 amendments apply only to two narrow clauses. Everything else in the rewrite waits.
You may still have a THCA pre-roll, a 5 mg seltzer, or delta-8 gummies that were sold as hemp. The legal theory those products sit on has two dates now, and they are not the same date for every molecule.
| Date | What changes (federal hemp definition) |
|---|---|
| Thursday, November 12, 2026 | Intermediate and final hemp-derived products that contain cannabinoids not capable of being naturally produced by Cannabis sativa L. — including acetylated molecules such as THC-O acetate — fall outside the federal hemp definition under Public Law 119-37 as amended. Section 2019 of Public Law 119-103 did not delay this piece. |
| Friday, December 11, 2026 | The total-THC test (THCA counts toward 0.3% dry weight), cannabinoids the plant can make but that were synthesized or manufactured outside the plant, intermediate limits, and the 0.4 mg combined total THC per container cap. The Delay Amendment keeps these on December 11. |
FDA still has not published the three cannabinoid lists or the container guidance Congress ordered within 90 days of enactment. Congressional Research Service Legal Sidebar LSB11496, dated October 28, 2026, says that as of that date FDA had published none of those items (CRS LSB11496; CannabisNews.org summary). That gap does not stop the statutory dates from arriving. It leaves sorting disputes, such as converted delta-8, unresolved in agency text.
This is education about public law, not legal advice. Rules in your state may move sooner or stay stricter.
What changes on November 12, and what waits until December 11?
Section 781 was written to take effect 365 days after November 12, 2025, which is November 12, 2026. Section 2019 then limited that early application. Until December 11, 2026, the amendments “shall only apply” to products described in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) of the amended hemp definition. Those two clauses are the same idea, once for an intermediate product and once for a final product: cannabinoids that are “not capable of being naturally produced” by a Cannabis sativa L. plant.
| What the statute changes | Where it sits | When it applies |
|---|---|---|
| Cannabinoids the plant cannot naturally produce, in an intermediate or final product | (1)(C)(ii)(I) and (1)(C)(iv)(I) | November 12, 2026 |
| Total THC, including THCA, at 0.3% on a dry-weight basis | (1)(A) | December 11, 2026 |
| Cannabinoids the plant can produce, but that were synthesized or manufactured outside the plant | (1)(C)(ii)(II) and (1)(C)(iv)(II) | December 11, 2026 |
| A final product over 0.4 mg combined total per container | (1)(C)(iv)(III) | December 11, 2026 |
| An intermediate product over 0.3% combined total, or one sold straight to a consumer | (1)(C)(ii)(III) and (1)(C)(iii) | December 11, 2026 |
THC-O acetate is the clearest November 12 example people use, because acetylation adds a group the plant does not make. The statute does not print the name “THC-O.” It prints the category. The molecule-by-molecule lists Congress told FDA to publish have not appeared. CRS LSB11496 (October 28, 2026) confirmed FDA had still not published any of them (CRS). A search of FDA and Federal Register materials on November 10, 2026 did not turn up a later list.
Converted delta-8 is the disputed case. The statute’s second prong covers a cannabinoid the plant can make that was “synthesized or manufactured outside the plant.” Delta-8 occurs in the plant in trace amounts, and the commercial product is usually made by converting CBD in a lab. On the face of the text, that is prong II, and Section 2019 does not accelerate prong II. That reading lands on December 11. Other analyses put lab-converted delta-8 on November 12, because FDA still has not said which cannabinoids count as “capable of being naturally produced.” MJBizDaily reported that split in September 2026. This article states both readings. It does not pick a winner the statute does not name.
The chemistry of the total-THC test is in total THC versus delta-9. The state patchwork is in the 2026 hemp and cannabis landscape. The state-by-state table for delta-8 is in Is Delta-8 Legal? Federal Dates and a State-by-State Table.
The law, and where the two dates come from
The original provision is Section 781 of Public Law 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. It was the bill that ended the 2025 shutdown. The hemp rewrite rode along inside it.
Section 781 opens like this:
“Effective 365 days after the enactment of this Act, Section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o) is amended…”
Enactment was November 12, 2025. Add 365 days and you land on November 12, 2026. That sentence is still in the statute. What changed is how much of it is allowed to operate on that day.
Public Law 119-103, the Continuing Appropriations and Extensions Act, 2027 (H.R. 6500), was approved September 2, 2026. Section 2019, at 140 Stat. 1003, reads:
“Until December 11, 2026, the amendments made by section 781 of division B of Public Law 119–37 (7 U.S.C. 1639o note) shall only apply with respect to products described in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) of section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o) (as amended by such section 781).”
“Shall only apply” is the whole mechanism. The amendments exist. Until December 11 they reach only those two clauses. On December 11 the limitation ends, and the rest of Section 781 — whose own effective date has already arrived — applies.
What follows is not a new ban printed in those words. It is a new definition of “hemp.” Everything the 2018 Farm Bill made possible sat on that definition. Change the definition and the ground moves under the category.
There are three operative changes. Here they are, with the date each one actually gets.
Change 1: THCA counts toward the 0.3% limit on December 11
The new definition reads:
“The term ‘hemp’ means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of not more than 0.3 percent on a dry weight basis.”
Compare that to the old standard, which measured delta-9 THC only.
This sentence lives in paragraph (1)(A). Section 2019 does not name (1)(A). The total-THC test, including for THCA flower, is a December 11 change.
Why this is the change that matters most
Raw cannabis does not contain much delta-9 THC. It contains THCA — tetrahydrocannabinolic acid, the acidic precursor. THCA is not intoxicating on its own. Heat converts it. Light a joint, hit a vaporizer, or bake a tray of flower, and THCA loses a carboxyl group and becomes delta-9 THC.
So a flower that tests at 0.2% delta-9 THC and 25% THCA passes an old-standard lab test and gets you high anyway. That gap is the commercial basis of THCA flower, a product that is chemically close to dispensary cannabis and was sold as federally lawful hemp.
The new text closes the gap by naming THCA directly, in parentheses, inside the definition. It does that on December 11, 2026, not on November 12.
The arithmetic, and what the statute leaves out
Chemists convert THCA to its THC equivalent using the ratio of the two molecules’ weights — roughly 0.877, because THCA is a slightly heavier molecule that sheds part of itself during decarboxylation.
Run that on typical flower. At 20% THCA, the THC-equivalent contribution alone is about 17.5%. The threshold is 0.3%. It is not a near miss.
Two honest caveats. First, the section quoted above does not supply a formula. It says “total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid)” and stops. How that gets calculated in a compliance test sits in testing regulation, not in this text.
Second, note the reach of the phrase “and any part of that plant… and all derivatives, extracts, cannabinoids, isomers, acids, salts.” The 0.3% ceiling is not applied only to a plant in a field. It travels to extracts. A high-potency distillate is not 0.3% anything. Read plainly, concentrated extracts do not clear this bar on their own, once the sentence is in force.
Change 2: Cannabinoids made outside the plant, on two dates
The statute excludes hemp-derived cannabinoid products containing:
“(I) cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant;
(II) cannabinoids that — (aa) are capable of being naturally produced by a Cannabis sativa L. plant; and (bb) were synthesized or manufactured outside the plant…”
Prong I covers molecules the plant does not make. Section 2019 names prong I, in both the intermediate clause and the final-product clause. That is the November 12 category.
Prong II covers molecules the plant does make, but that were produced somewhere other than inside a plant. Section 2019 does not name prong II. That is the December 11 category, unless a later law or a binding agency list sorts a specific molecule into prong I.
That second prong is what retires the old industry defense, “it occurs in nature,” once December 11 arrives. The question stops being whether a cannabinoid can exist naturally. It becomes where the molecule in the package actually came from.
Commercial delta-8 THC is not extracted from plants in meaningful quantity. It is made by chemically converting CBD. Same for most HHC on the market, and for most HHC and THCP products sold as hemp. If the molecule is one the plant can produce, prong II points to December 11. If FDA or a court decides the commercial form is not “capable of being naturally produced,” prong I points to November 12. That is the dispute. It is not resolved in the statute’s text.
Which cannabinoids land in which bucket was supposed to be settled by lists. Section 781 directs the FDA, within 90 days of the November 12, 2025 enactment, to publish:
- a list of all cannabinoids known to be capable of being naturally produced by the plant, as reflected in peer-reviewed literature;
- a list of all tetrahydrocannabinol class cannabinoids known to occur naturally in the plant;
- a list of other cannabinoids with similar effects to — or marketed to have similar effects to — THC-class cannabinoids;
- more detail on the term “container.”
Those four lists do an enormous amount of the actual work. They are where a molecule like THCP gets sorted. The 90-day deadline fell in February 2026. CRS LSB11496 (October 28, 2026) reported that FDA had published none of the required lists or the container guidance as of that date.
One more line, because it closes an obvious workaround. The statute also excludes intermediate hemp products “which are marketed or sold as a final product or directly to an end consumer for personal or household use.” That exclusion is paragraph (1)(C)(iii). Section 2019 does not name it, so it is a December 11 rule. Selling bulk material straight to the public does not convert it into something else, once that clause applies.
Change 3: 0.4 milligrams per container, on December 11
This is the provision that reshapes retail hemp, and it is not a November 12 rule. It sits in paragraph (1)(C)(iv)(III). Section 2019 names (iv)(I), not (iv)(III).
The statute sets two different ceilings depending on where a product sits in the supply chain.
Intermediate hemp-derived cannabinoid products — powders, liquids, oils, anything meant to be formulated into something else — are excluded if they contain “more than 0.3 percent combined total” of total tetrahydrocannabinols and similar-effect cannabinoids. That is (ii)(III). December 11.
Final products — the thing on the shelf — are excluded if they contain:
“greater than 0.4 milligrams combined total per container of — (aa) total tetrahydrocannabinols (including tetrahydrocannabinolic acid); and (bb) any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).”
Three things to notice, once that sentence is in force.
It is per container, not per serving
The statute defines the term, and the definition is narrow:
“The term ‘container’ means the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product in which the final hemp-derived cannabinoid product is enclosed for retail sale to consumers, such as a jar, bottle, bag, box, packet, can, carton, or cartridge.”
Innermost. Not the shipping box. The list names a cartridge explicitly.
Because the cap is per container rather than per dose, a thirty-serving bottle gets the same 0.4 mg ceiling as a single gummy. That is what “per container” means. It puts multi-serving formats — full-spectrum tinctures, bottles of softgels, bags of gummies — under more pressure than single units.
The math on beverages is not close
A hemp-derived THC seltzer in the popular low-dose range carries 5 mg per can. The can is the innermost vessel, so the can is the container.
5 mg against a 0.4 mg ceiling is more than twelve times over. Even a 2.5 mg can sits at roughly six times the cap. There is no reformulation that gets a recognizably intoxicating drink under 0.4 mg.
You cannot swap in a different cannabinoid
The cap is a combined total, and clause (bb) sweeps in “any other cannabinoids that have similar effects (or are marketed to have similar effects).” A product can be captured by how it is marketed, independent of a lab’s pharmacology call. Building a drink around HHC or THCP instead of delta-9 does not route around a rule written this way, once December 11 arrives.
| The change | What the text says | When | What it plausibly reaches |
|---|---|---|---|
| Total THC standard | “total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of not more than 0.3 percent” | December 11, 2026 | THCA flower, THCA pre-rolls, high-potency extracts |
| Plant-impossible cannabinoids | cannabinoids “not capable of being naturally produced” | November 12, 2026 | THC-O acetate and other molecules the plant does not make |
| Outside-the-plant exclusion | cannabinoids “synthesized or manufactured outside the plant” | December 11, 2026, unless sorted into the November 12 clause | Converted delta-8, most HHC, most novel-cannabinoid vapes — the sorting is disputed |
| Container cap | “greater than 0.4 milligrams combined total per container” | December 11, 2026 | THC seltzers, gummies, tinctures, most edibles sold outside dispensaries |
What’s still legal after November 12 and December 11
This section is a plain-language map of what the federal hemp definition still covers. It is not legal advice, dosing guidance, or a promise about enforcement in your state.
After November 12, 2026, products built around cannabinoids the plant cannot naturally produce — THC-O acetate is the usual example — are not federal hemp under the amended definition. That is separate from whether a shop still sells them or whether state police act on the first day.
After December 11, 2026, these categories remain eligible to be hemp only if they clear every test in the statute:
- Industrial hemp fiber, grain, oil, stalk materials, and other non-intoxicating uses spelled out in the amendment.
- Compliant CBD and other non-intoxicating cannabinoids in products that stay at or under 0.4 mg combined total THC per container (innermost retail package) once the container rule applies.
- Hemp seed, hemp hearts, and similar food-grade materials that were never “hemp-derived cannabinoid products” in the first place.
- FDA-approved drug products carved out of the hemp-product definition.
- State-licensed medical or adult-use cannabis sold under state marijuana law — a different lane entirely from federal hemp.
Delta-8, most commercial HHC, THCA flower, standard THC gummies, and hemp THC drinks ride the December 11 rules, not the November 12 synthetic-cannabinoid clause — unless FDA’s unpublished lists or a court sorts a specific molecule into the November 12 bucket. Converted delta-8 is the live dispute this article keeps in both columns.
What the law leaves alone
Not everything hemp is in scope, and the exclusions are specific. These carve-outs are part of the same amendment, so they arrive with the December 11 text rather than as a separate November 12 regime.
Industrial hemp is expressly included in the definition and carved out by use: stalk and fiber, whole grain, oil, cake, nut and hull, non-cannabinoid derivatives, microgreens and edible hemp leaf grown from compliant seed, research plants that never enter commerce, and seed grown to produce those materials. Rope, hempcrete, hemp hearts, and textiles are not what this section is about.
FDA-approved drugs are excluded from the term “hemp-derived cannabinoid product” — specifically drugs approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act. A prescription cannabidiol medication is regulated as a drug and is not touched by this.
State-licensed marijuana is a separate legal universe. If you buy from a licensed dispensary in a legal state, your products were never federal hemp. They are governed by state law and by the Controlled Substances Act, not by Section 781. Our state-by-state guide covers that map.
CBD itself is not named as excluded. A CBD product stays inside the definition on its own terms — but, from December 11, it still has to clear 0.4 mg of combined total THC per container. For broad-spectrum and isolate products that is straightforward. For full-spectrum formats carrying trace THC across many servings in one bottle, it is a real question.
What the text still does not tell you
Everything above is reading. Everything below is labeled as such, because the distinction is the point.
The statute does not say “banned.” It says these things are not hemp. The consequences flow through other laws — principally the Controlled Substances Act, which treats marijuana as a controlled substance except where the hemp definition carves it out. Shrink the carve-out and more material falls back under the CSA. That is the mechanism most lawyers expect. It is a reasonable reading. It is not printed as an enforcement order in Section 781.
Enforcement is genuinely unknown. A definition changing in the Agricultural Marketing Act does not come with an enforcement budget or a lead agency. Whether December 12, 2026 looks like coordinated action, a squeeze on payment processors and shipping, or very little visible change is not something the text answers.
States are already moving on their own timelines, in both directions. Some have banned intoxicating hemp outright. Some have built regulated frameworks. A federal definition sets a floor for the federal category. States can be stricter, and several already are. Your state’s rules may matter more in practice than either federal date, especially if you cross state lines.
Litigation is likely. A large industry with two date-certain deadlines is a strong candidate for legal challenge. This article does not predict how courts will rule.
Congress already moved most of the date once. Section 2019 is that move: 29 days, and only for the clauses it does not name. Congress can amend the dates again before December 11. As of October 8, 2026, no later public law has done so. I did not find a USDA or FDA statement that sets a different effective date. The slip law is the controlling text.
This is separate from rescheduling
A quick untangling, because the two stories run together constantly.
In April 2026, DEA and DOJ issued a final rule moving marijuana from Schedule I to Schedule III — but only for products in an FDA-approved drug product, or subject to a state-issued license to manufacture, distribute, or dispense marijuana for medical purposes (91 FR 22714, effective April 28, 2026). Adult-use cannabis that is outside those categories was not covered and remains Schedule I. A separate hearing on broader rescheduling (91 FR 22777) opened June 29, 2026, and has not concluded.
We break the split down in our Schedule III explainer, and the broader picture sits in our 2026 legalization roundup.
The point for now: rescheduling and the hemp definition are two different tracks. Nothing in the April rescheduling changes November 12 or December 11. Nothing in Section 781 changes marijuana’s schedule.
What to actually do before the dates
Practical, not alarmist.
Learn your state’s rules first. For most people the state answer arrives sooner and hits harder than either federal date.
Know what you are actually buying. If a product’s legality rests on a delta-9-only measurement, that foundation has a date on it: December 11 for the total-THC test and the container cap, November 12 only for cannabinoids the plant cannot make. Reading a certificate of analysis tells you what is in the package. That skill is worth having anyway, given how unreliable potency labels can be.
Do not treat “hemp-derived” as a safety signal. It never was one. It was a measurement standard. Unregulated intoxicating products have caused real harm, including pediatric emergencies from hemp-derived THC edibles and sales to minors.
If you use cannabis to sleep or manage pain, think about supply before December, not in a panic on November 12. A licensed dispensary in a legal state is not affected by this provision. Whether that is available to you depends on where you live.
Do not assume a drug test cares about any of this. Legal status and what shows up in a urine screen are unrelated questions.
The part that outlasts the statute
Congress defined hemp by measurement and origin — how much total cannabinoid, produced where. Not by plant name. Not by strain. Not by the word on the jar. Section 2019 then split that definition across two dates. The measurement did not change. The calendar did.
The science keeps handing us that same lesson from the other direction. Two jars of the same Blue Dream can differ substantially in cannabinoid and terpene content, and the budtender recommending it may have been on the job for three weeks. What is actually in the product, and how your body responds to it, is the real information. Whether you are chasing something calming or balanced, the ratio you land on matters more than the category label.
Lawmakers and lab chemists have landed in the same place: chemistry is the thing that is real. If you track what you took, how much, and how it actually landed, you own that data no matter which products stay on the shelf. That is what the High IQ app is for.
Key takeaways
- November 12, 2026 is no longer the date for the whole hemp rewrite. It is the date for products that contain a cannabinoid the plant cannot naturally produce.
- December 11, 2026 is the date for total THC including THCA, the 0.4 mg per-container cap, and cannabinoids the plant can make but that were manufactured outside it.
- Converted delta-8 is disputed. The statutory cross-reference points to December 11. Without FDA’s list, some analyses still put it on November 12.
- Dispensary cannabis is a different legal category. Section 781 does not rewrite state-licensed marijuana.
- Congress already delayed most of this once. It can do so again. As of October 8, 2026, Section 2019 is the delay that is law.
FAQ
What is the difference between the November 12 and December 11 hemp dates?
November 12, 2026 is the original Section 781 effective date, and it still applies to one category: intermediate and final products that contain cannabinoids “not capable of being naturally produced” by the cannabis plant. December 11, 2026 is when Public Law 119-103 stops limiting the rest of Section 781. That is the total-THC test, THCA flower, the 0.4 mg container cap, and cannabinoids the plant can produce but that were synthesized or manufactured outside it.
Will THCA flower lose its federal hemp status on November 12, 2026?
No. The total-THC sentence, which counts THCA toward the 0.3% dry-weight ceiling, is not one of the two clauses Section 2019 lets apply early. It applies on December 11, 2026. Typical THCA flower is far above 0.3% total. The statute does not use the word “illegal.” Products that fall outside the hemp definition are widely expected to be treated as controlled substances. Enforcement is not described in the text.
Does converted delta-8 change on November 12 or December 11?
The statute does not name delta-8. Commercial delta-8 is usually made outside the plant from CBD, and delta-8 also occurs naturally in trace amounts. That combination matches the “synthesized or manufactured outside the plant” clause, which Section 2019 does not accelerate, so the text points to December 11. Lawyers disagree, because FDA has not published the list of cannabinoids the plant can naturally produce. Treat the date for a specific delta-8 product as unsettled until that list, or a court, sorts it.
Can a hemp THC seltzer stay legal under the 0.4 mg cap?
Not as federal hemp, once the cap applies, if the can holds more than 0.4 mg combined total. A common 5 mg can is more than twelve times that ceiling. The cap is a December 11, 2026 rule, not a November 12 rule. The same per-container ceiling is what full-spectrum CBD bottles have to clear. State-licensed dispensary drinks are a different legal category.
Does this affect cannabis bought at a state-licensed dispensary?
No. Dispensary products in state-legal markets were never sold as federal hemp. They are governed by state law and by the Controlled Substances Act. Section 781 and Section 2019 do not reach them. Adult-use marijuana outside the April 2026 Schedule III categories remains Schedule I. That schedule question is separate from these two hemp dates.
A necessary note
This is not legal advice. I am an educator reading public statutes, not your attorney. Cannabis and hemp law varies by state, changes quickly, and the practical consequences depend on agency action and court decisions that are not finished. If you have a business, an inventory, a professional license, or any real exposure here, talk to a lawyer in your jurisdiction. Do not make decisions based on a blog post, including this one.
Sources
Primary statutory and regulatory text, read directly on October 8, 2026:
- Public Law 119-37, Section 781 — Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. Approved November 12, 2025. Section 781 is effective 365 days after enactment and amends Section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o). Page cite 139 Stat. 558–561. govinfo.gov
- Public Law 119-103, Section 2019 — Continuing Appropriations and Extensions Act, 2027 (H.R. 6500). Approved September 2, 2026. 140 Stat. 987; Section 2019 at 140 Stat. 1003. Until December 11, 2026, the Section 781 amendments apply only to 7 U.S.C. 1639o(1)(C)(ii)(I) and (1)(C)(iv)(I) as amended. congress.gov slip law (PDF)
- Congressional Research Service, IF13136 — Changes to the Statutory Definition of Hemp. Describes the Section 781 amendments, the FDA list requirement, and, in the version current on Congress.gov, the September 2, 2026 delay in P.L. 119-103. congress.gov
- Congressional Research Service, LSB11496 — Delay in Changes to Hemp Definition: Cannabinoids Not Capable of Being Naturally Produced by the Cannabis Plant. Dated October 28, 2026. Confirms FDA had not published the three cannabinoid lists or container guidance as of that date. everycrsreport.com
- MJBizDaily (accessed October 8, 2026) — reporting that lawyers disagree on whether converted delta-8 falls on November 12 or December 11, because FDA has not published the cannabinoid lists. Used only for the existence of that dispute, not as a substitute for the statute. mjbizdaily.com
- 91 FR 22714 — Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III. Department of Justice / Drug Enforcement Administration. Final rule published and effective April 28, 2026. federalregister.gov
- 91 FR 22777 — Schedules of Controlled Substances: Rescheduling of Marijuana. Notice of hearing, Docket DEA-1362. Published April 28, 2026; hearing began June 29, 2026. federalregister.gov
Quoted statutory language is taken from the slip laws linked above. Where this article characterizes consequences rather than quoting text, it says so. No USDA or FDA notice located on October 8, 2026 sets an effective date different from Section 781 and Section 2019.